Beta-blocker therapy for congestive heart failure: A systematic overview and critical appraisal of the published trials

Canadian Journal of Cardiology

Volumn 14, Issue 8, 1998, Pages 1045-1053

  Avezum, Alvaro ^a   Tsuyuki, Ross T ^b,c   Pogue, Janice ^b   Yusuf, Salim ^c  

^a INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Beta blockers; Congestive heart failure; Meta analysis

Indexed keywords

ACEBUTOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LABETALOL; METOPROLOL; NEBIVOLOL; PLACEBO; VASODILATOR AGENT;

BRADYCARDIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DATA ANALYSIS; EXERCISE; FATIGUE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HOSPITALIZATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; META ANALYSIS; METHODOLOGY; MORBIDITY; MORTALITY; PATIENT MONITORING; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; REVIEW; STATISTICAL ANALYSIS; SYNCOPE; VERTIGO;

ADRENERGIC BETA-ANTAGONISTS; CLINICAL TRIALS; DRUG EVALUATION; EVALUATION STUDIES; HEART FAILURE, CONGESTIVE; HUMANS; REPRODUCIBILITY OF RESULTS;

EID: 0031670458     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham Study. N Engl J Med 1971;285:1441-6.
2. Yusuf S, Thorn T, Abbot RD. Changes in hypertension and in congestive heart failure mortality. Hypertension 1989; (Suppl I);13:174-9.
3. Kannel WB, Belanger AJ. Epidemiology in heart failure. Am Heart J 1991:121:951-7.
4. Schocken DD, Arriera Ml, Leaverton PE. Prevalence in mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992;20:301-6.
5. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107-15.
6. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995:273:1450-6.
7. Packer M. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
8. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. N Engl J Med 1982;307:205-11.
9. Bristow MR, Port JD, Sandoval AB, Rasmussen R, Ginsburg R, Feldman AM. Beta-adrenergic receptor pathways in the failing human heart. Heart Fail 1989;5:77-90.
10. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984:311:819-23.
11. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-6.
12. Francis OS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87(SupplVI):VI40-8.
13. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. The SOLVD Investigators. Circulation 1990;82:1724-9.
14. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993:342:1441-6.
15. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994:90:1765-73.
16. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N EnglJ Med 1996:334:1349-55.
17. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 1997:349:375-80.
18. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-7.
19. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247:1707-14.
20. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-10.
21. Herlitz J, Hjalmarson A, Holmberg S, et al. Development of congestive heart failure after treatment with metoprolol in acute myocardial infarction. Br Heart J 1984:51:539-44.
22. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985:27:335-71.
23. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992:45:769-73.
24. Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomized controlled trials. Lancet 1998;351:47-52.
25. Ikram H, Fitzpatrick D. Double-blind trial of chronic oral beta blockade in congestive cardiomyopathy. Lancet 1981;ii:490-2.
26. Anderson JL, Lutz JR, Gilbert EM, et al. A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985;55:471-5.
27. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985;72:536-46.
28. Cucchini F, Compostella L, Papalia D, de Domenico R, lavernaro A, Zeppellini R. Trattamento cronico della cardiomiopatia dilatativa con betabloccanti. G Ital Cardiol 1988;18:835-42.
29. Gilbert EM, Anderson JL, Deitchman D, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double-blind, randomized study of bucindolol versus placebo. Am J Med 1990:88:223-9.
30. Leung W-H, Lau C-P, Wong C-K, Cheng C-H, Tai Y-T, Lim S-P. Improvement in exercise performance and hemodynamics by labetalol in patients with idiopathic dilated cardiomyopathy. Am Heart J 1990;119:884-90.
31. Pollock SO, Lystash J, Tedesco C, Craddock G, Smucker ML. Usefulness of bucindolol in congestive heart failure. Am J Cardiol 1990;66:603-7.
32. Woodley SL, Gilbert EM, Anderson JL, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991:84:2426-41.
33. Boutelant S, Lechat P, Komajda M, et al. Évaluation non invasive des effets cardiovasculaires du nébivolol chez l'insuffisant cardiaque. Arch Mal Coeur 1992:85:863-70.
34. Paolisso G, Gambardella A, Marrazzo G, et al. Metabolic and cardiovascular benefits deriving from beta-adrenergic blockade in chronic congestive heart failure. Am Heart J 1992;123:103-10.
35. Wisenbaugh T, Katz I, Davis J, et al. Long-tenu (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993;21:1094-100.
36. Eichhorn EJ, Heesch CM, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: A randomized double-blind, placebo-controlled study. J Am Coll Cardiol 1994:24:1310-20.
37. Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischémie cardiomyopathy. Bucindolol Investigators. Circulation 1994:89:1632-42.
38. Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: A randomized trial. J Am Coll Cardiol 1994:23:943-50.
39. Yusuf S. Digoxin in heart failure: results of the recent digoxin investigation group trial in the context of other treatments for heart failure. Eur Heart J 1997:18:1685-8.
40. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991:325:293-302.
41. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997:336:525-33.
42. Zarembski DG, Nolan PE Jr, Slack MK, Lui CY. Meta-analysis of the use of low-dose beta-adrenergic blocking therapy in idiopathic dilated cardiomyopathy. Am] Cardiol 1996:77:1247-50.
43. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27-34.
44. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur Heart J 1997;18:560-5.